Polyrizon (PLRZ) Competitors $1.01 0.00 (0.00%) As of 08/13/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock PLRZ vs. GBIO, JATT, OKUR, TPST, RNTX, LSTA, BDRX, NNVC, TENX, and MIRAShould you be buying Polyrizon stock or one of its competitors? The main competitors of Polyrizon include Generation Bio (GBIO), JATT Acquisition (JATT), OnKure Therapeutics (OKUR), Tempest Therapeutics (TPST), Rein Therapeutics (RNTX), Lisata Therapeutics (LSTA), Biodexa Pharmaceuticals (BDRX), NanoViricides (NNVC), Tenax Therapeutics (TENX), and MIRA Pharmaceuticals (MIRA). These companies are all part of the "pharmaceutical products" industry. Polyrizon vs. Its Competitors Generation Bio JATT Acquisition OnKure Therapeutics Tempest Therapeutics Rein Therapeutics Lisata Therapeutics Biodexa Pharmaceuticals NanoViricides Tenax Therapeutics MIRA Pharmaceuticals Generation Bio (NASDAQ:GBIO) and Polyrizon (NASDAQ:PLRZ) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership. Does the media refer more to GBIO or PLRZ? In the previous week, Generation Bio had 9 more articles in the media than Polyrizon. MarketBeat recorded 10 mentions for Generation Bio and 1 mentions for Polyrizon. Polyrizon's average media sentiment score of 1.88 beat Generation Bio's score of -0.26 indicating that Polyrizon is being referred to more favorably in the news media. Company Overall Sentiment Generation Bio Neutral Polyrizon Very Positive Is GBIO or PLRZ more profitable? Polyrizon has a net margin of 0.00% compared to Generation Bio's net margin of -341.12%. Polyrizon's return on equity of 0.00% beat Generation Bio's return on equity.Company Net Margins Return on Equity Return on Assets Generation Bio-341.12% -82.30% -31.89% Polyrizon N/A N/A N/A Do analysts rate GBIO or PLRZ? Generation Bio currently has a consensus target price of $37.33, suggesting a potential upside of 464.80%. Given Generation Bio's stronger consensus rating and higher possible upside, analysts plainly believe Generation Bio is more favorable than Polyrizon.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Generation Bio 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Polyrizon 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders have more ownership in GBIO or PLRZ? 95.2% of Generation Bio shares are held by institutional investors. 21.8% of Generation Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has better earnings & valuation, GBIO or PLRZ? Polyrizon has lower revenue, but higher earnings than Generation Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGeneration Bio$19.89M2.24-$131.67M-$10.82-0.61PolyrizonN/AN/A-$1.54MN/AN/A SummaryGeneration Bio beats Polyrizon on 7 of the 12 factors compared between the two stocks. Get Polyrizon News Delivered to You Automatically Sign up to receive the latest news and ratings for PLRZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PLRZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLRZ vs. The Competition Export to ExcelMetricPolyrizonMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.05M$3.03B$5.54B$9.82BDividend YieldN/A2.27%4.62%4.11%P/E RatioN/A20.6730.1526.03Price / SalesN/A363.56461.34104.73Price / CashN/A42.0537.7558.93Price / Book0.007.638.496.06Net Income-$1.54M-$54.65M$3.26B$265.11M7 Day Performance-12.93%5.41%4.19%3.38%1 Month Performance48.07%7.14%4.64%2.28%1 Year PerformanceN/A31.27%35.15%29.67% Polyrizon Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLRZPolyrizonN/A$1.01flatN/AN/A$6.05MN/A0.00N/APositive NewsGBIOGeneration Bio3.7699 of 5 stars$4.14-3.3%$80.00+1,832.4%-73.9%$27.75M$24.56M-0.38150News CoverageEarnings ReportAnalyst ForecastGap UpJATTJATT AcquisitionN/A$1.57+7.5%N/A-55.3%$27.08MN/A0.003High Trading VolumeOKUROnKure Therapeutics3.2734 of 5 stars$2.00-2.2%$32.33+1,520.7%N/A$26.82MN/A-0.38N/AEarnings ReportGap UpTPSTTempest Therapeutics3.092 of 5 stars$7.03-0.6%$30.00+327.0%-34.7%$25.94MN/A-0.3920Positive NewsEarnings ReportRNTXRein TherapeuticsN/A$1.11-3.9%N/AN/A$25.59MN/A-0.399LSTALisata Therapeutics2.5776 of 5 stars$2.93-1.0%$23.50+701.8%-8.5%$25.47M$1M-1.2830Earnings ReportGap DownBDRXBiodexa Pharmaceuticals0.2009 of 5 stars$6.95+2.7%N/AN/A$25.35M$470K0.0020Positive NewsNNVCNanoViricides0.268 of 5 stars$1.58-0.9%N/A-13.8%$25.31MN/A-2.1920TENXTenax Therapeutics2.1738 of 5 stars$5.98-2.1%$17.50+192.7%+46.7%$24.80MN/A-2.419News CoverageEarnings ReportMIRAMIRA Pharmaceuticals2.3627 of 5 stars$1.39-3.1%$17.00+1,127.4%-27.3%$23.59MN/A-2.732 Related Companies and Tools Related Companies Generation Bio Alternatives JATT Acquisition Alternatives OnKure Therapeutics Alternatives Tempest Therapeutics Alternatives Rein Therapeutics Alternatives Lisata Therapeutics Alternatives Biodexa Pharmaceuticals Alternatives NanoViricides Alternatives Tenax Therapeutics Alternatives MIRA Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PLRZ) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredGet This Stock NowThis company is the lifeblood of AI data centers, yet almost no one has caught up with the story. Their hardwa...InvestorPlace | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Polyrizon Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Polyrizon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access